Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$115.87
-$4.08(-5.19%)
At close: 4:00 PM EST
$115.87
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)1.43M
Market Cap
$2.34B
Enterprise Value$2.93B
Total Cash (Recent Filing)$461.74M
Total Debt (Recent Filing)$863.41M
Price to Earnings (P/E)13.5
Beta1.11
Next Earnings
Jul 30, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.03
Shares Outstanding34,560,910
10 Day Avg. Volume1,038,121
30 Day Avg. Volume1,430,986
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit7.80
Enterprise Value/Ebitda20.98
Forecast
1Y Price Target
$120.25Price Target Upside3.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.01
Revenue Forecast (FY)$733.04M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive free cash flow and FCF running ~69% of net income provide durable internal funding for R&D, NOP logistics and Gen‑3 product rollouts. This reduces reliance on external financing, supports iterative product upgrades and funds transitory operational investments over the next 2–6 months.
Improved ProfitabilityA material multi-year profitability inflection with TTM net margin near 27% indicates structural improvement in unit economics and pricing power from consumables and services. Sustained margins enhance reinvestment capacity and make earnings less sensitive to transient revenue swings over the medium term.
Business Model & Growth RoadmapRecurring consumables per transplant plus expanding services (NOP aircraft/logistics) create high visibility, recurring revenue. The clear product and clinical roadmap (Gen‑3, CHOPS, European NOP expansion) supports sustained adoption and higher lifetime revenue per installed base over the next several quarters.
Bears Say
Rising LeverageA material jump in leverage reduces financial flexibility and raises fixed obligations if growth or margins slow. Higher debt makes the company more sensitive to margin pressure or clinical timing risks, potentially constraining discretionary investments or forcing cost cutting within a 2–6 month window.
Margin Compression From Front-Loaded InvestmentManagement is deliberately front-loading R&D and NOP buildout, which compresses gross and operating margins near term. If expected returns or enrollment timelines slip, this investment-led margin erosion could persist beyond a single quarter and weigh on free cash flow and operating leverage in coming months.
Execution & Volume Risk From Clinical DelaysClinical enrollment delays and OPTN modernization–driven donor-volume volatility create tangible execution risk for consumable demand and new product approvals. Delays can push out revenue recognition for Gen‑3 launches and NOP expansion, producing durable timing uncertainty over the next several quarters.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $2.34B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on May 05, 2026. The company reported $0.3 earnings per share for the quarter, missing the consensus estimate of $0.598 by -$0.298.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Undervalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.54.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,560,910 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $0.3 in its last earnings report, missing expectations of $0.598. Following the earnings report the stock price went down -23.186%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.25 (3.78% Upside)
$120.25 (3.78% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 93%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 691.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.43%
12-Months-Change
Fundamentals
Return on Equity
41.92%
Trailing 12-Months
Asset Growth
71.32%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates solid top-line growth (21% YoY) and a strong cash position (~$462M), supported by clear, multi-year growth initiatives (CHOPS, OCS Kidney Gen 3.0, Gen 3.0 upgrades, and European NOP expansion) and reiterated full‑year guidance (20%–25% revenue growth). Near term, the company is absorbing deliberate, sizeable investments that compress gross and operating margins (gross margin down ~331 bps YoY; adjusted operating expenses up ~42% YoY), while donor-volume volatility and prior competitive-driven enrollment delays create execution and timing risk for clinical programs. Overall the call strikes a positive tone on growth and strategic direction but acknowledges tangible near-term margin and enrollment headwinds.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$120.25
▲(3.78% Upside)
Technical Analysis
Ownership Overview
3.61% Insiders
42.76% Mutual Funds
22.41% Other Institutional Investors
3.97% Public Companies and Individual Investors